Genmab Share Price Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.8B 2.88B 240B | Sales 2025 * | 23.62B 3.44B 286B | Capitalization | 132B 19.19B 1,598B |
---|---|---|---|---|---|
Net income 2024 * | 4.68B 682M 56.76B | Net income 2025 * | 6.63B 965M 80.36B | EV / Sales 2024 * | 5.33 x |
Net cash position 2024 * | 26.36B 3.84B 319B | Net cash position 2025 * | 33.63B 4.9B 408B | EV / Sales 2025 * | 4.16 x |
P/E ratio 2024 * |
29.9
x | P/E ratio 2025 * |
21.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 01/99/01 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01/07/01 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23/20/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01/17/01 |
Director/Board Member | 73 | 01/03/01 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01/16/01 |
1st Jan change | Capi. | |
---|---|---|
+9.39% | 115B | |
+11.69% | 106B | |
-2.56% | 21.96B | |
-13.99% | 21.87B | |
-4.57% | 18.08B | |
-38.29% | 17.71B | |
+7.88% | 14.32B | |
+35.98% | 12.42B | |
-24.23% | 8.23B |